Ellicott City, MD – The Society for Clinical Research Sites (SCRS) announces Acurian as the corporate sponsor for the SCRS Ambassador Program in Poland. The SCRS Site Ambassador Program brings SCRS benefits to sites in countries around the world. SCRS currently has site members in 49 countries. Countries (in some cases, regions) with an SCRS Site Ambassador receive quarterly SCRS seminars focused on the interests of sites in that area. “Acurian has taken a leadership position in the Ambassador Program by supporting our efforts in Poland,” said Christine Pierre, President of SCRS. “We look forward to supporting site sustainability in Poland and around the world as the SCRS Ambassador Program grows.” “We recognize that sites in Poland are increasingly crucial partners in the effort to successfully enroll global clinical trial programs we support,” said Todd Albin, Senior Director of Site Enrollment Optimization at Acurian, a subsidiary of PPD, a leading global contract research organization. “SCRS has been the global leader in advocating for the sustainability of sites throughout the world. We are very excited to be part of this ambassador program and help introduce Polish sites to SCRS and Acurian so that they can benefit from the variety of ways both of our organizations contribute to their long-term success.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About Acurian Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time. For more information, visit www.acurian.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.